Charles River Laboratories International (NYSE:CRL) CEO Birgit Girshick Sells 6,500 Shares

Charles River Laboratories International, Inc. (NYSE:CRL) CEO Birgit Girshick sold 6,500 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the sale, the chief executive officer directly owned 36,013 shares of the company’s stock, valued at approximately $10,080,038.70. This represents a 15.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Price Performance

CRL opened at $281.78 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. The company’s 50-day moving average price is $222.90 and its 200 day moving average price is $190.70. Charles River Laboratories International, Inc. has a fifty-two week low of $144.26 and a fifty-two week high of $288.02. The firm has a market cap of $13.45 billion, a price-to-earnings ratio of -58.10, a price-to-earnings-growth ratio of 2.95 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.Charles River Laboratories International’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, sell-side analysts expect that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on CRL shares. Barclays reiterated an “overweight” rating and issued a $300.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, August 5th. Weiss Ratings raised shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 1st. CLSA downgraded shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price objective on the stock. in a research report on Monday, July 20th. Royal Bank Of Canada boosted their target price on shares of Charles River Laboratories International from $215.00 to $282.00 and gave the company an “outperform” rating in a research note on Thursday, August 6th. Finally, Mizuho set a $264.00 target price on shares of Charles River Laboratories International in a research report on Monday. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Charles River Laboratories International currently has a consensus rating of “Moderate Buy” and a consensus target price of $255.65.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Cardinal Capital Management increased its holdings in shares of Charles River Laboratories International by 0.6% during the fourth quarter. Cardinal Capital Management now owns 10,928 shares of the medical research company’s stock valued at $2,180,000 after purchasing an additional 62 shares during the period. Asset Management One Co. Ltd. raised its stake in shares of Charles River Laboratories International by 4.0% during the fourth quarter. Asset Management One Co. Ltd. now owns 1,847 shares of the medical research company’s stock valued at $375,000 after purchasing an additional 71 shares in the last quarter. Glenmede Trust Co. NA lifted its holdings in Charles River Laboratories International by 2.8% in the first quarter. Glenmede Trust Co. NA now owns 2,706 shares of the medical research company’s stock worth $467,000 after purchasing an additional 73 shares during the period. Mercer Global Advisors Inc. ADV grew its position in Charles River Laboratories International by 1.3% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 6,316 shares of the medical research company’s stock valued at $1,260,000 after buying an additional 80 shares in the last quarter. Finally, Advisory Services Network LLC grew its position in Charles River Laboratories International by 2.6% in the 3rd quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock valued at $505,000 after buying an additional 83 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.